196 related articles for article (PubMed ID: 30869126)
1. Recombinant dermatan sulfate is a potent activator of heparin cofactor II-dependent inhibition of thrombin.
Tykesson E; Maccarana M; Thorsson H; Liu J; Malmström A; Ellervik U; Westergren-Thorsson G
Glycobiology; 2019 Jun; 29(6):446-451. PubMed ID: 30869126
[TBL] [Abstract][Full Text] [Related]
2. N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate.
Halldórsdóttir AM; Zhang L; Tollefsen DM
Glycobiology; 2006 Aug; 16(8):693-701. PubMed ID: 16624894
[TBL] [Abstract][Full Text] [Related]
3. Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin inhibition.
Hayakawa Y; Hirashima Y; Kurimoto M; Hayashi N; Hamada H; Kuwayama N; Endo S
FEBS Lett; 2002 Jul; 522(1-3):147-50. PubMed ID: 12095635
[TBL] [Abstract][Full Text] [Related]
4. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.
Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI
J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098
[TBL] [Abstract][Full Text] [Related]
5. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
[TBL] [Abstract][Full Text] [Related]
6. Active site for heparin cofactor II in low molecular mass dermatan sulfate. Contribution to the antithrombotic activity of fractions with high affinity for heparin cofactor II.
Mascellani G; Liverani L; Parma B; Bergonzini G; Bianchini P
Thromb Res; 1996 Oct; 84(1):21-32. PubMed ID: 8885144
[TBL] [Abstract][Full Text] [Related]
7. Role of lysine 173 in heparin binding to heparin cofactor II.
Whinna HC; Blinder MA; Szewczyk M; Tollefsen DM; Church FC
J Biol Chem; 1991 May; 266(13):8129-35. PubMed ID: 1902471
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin.
Liaw PC; Becker DL; Stafford AR; Fredenburgh JC; Weitz JI
J Biol Chem; 2001 Jun; 276(24):20959-65. PubMed ID: 11294849
[TBL] [Abstract][Full Text] [Related]
9. Dermatan sulfate in tunicate phylogeny: order-specific sulfation pattern and the effect of [→4IdoA(2-sulfate)β-1→3GalNAc(4-sulfate)β-1→] motifs in dermatan sulfate on heparin cofactor II activity.
Kozlowski EO; Lima PC; Vicente CP; Lotufo T; Bao X; Sugahara K; Pavão MS
BMC Biochem; 2011 May; 12():29. PubMed ID: 21619699
[TBL] [Abstract][Full Text] [Related]
10. Binding of heparin or dermatan sulfate to thrombin is essential for the sulfated polysaccharide-accelerated inhibition of thrombin by heparin cofactor II.
Yamagishi R; Koide T; Sakuragawa N
FEBS Lett; 1987 Dec; 225(1-2):109-12. PubMed ID: 3691797
[TBL] [Abstract][Full Text] [Related]
11. A unique dermatan sulfate-like glycosaminoglycan from ascidian. Its structure and the effect of its unusual sulfation pattern on anticoagulant activity.
Pavão MS; Mourão PA; Mulloy B; Tollefsen DM
J Biol Chem; 1995 Dec; 270(52):31027-36. PubMed ID: 8537360
[TBL] [Abstract][Full Text] [Related]
12. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity.
Maimone MM; Tollefsen DM
J Biol Chem; 1990 Oct; 265(30):18263-71. PubMed ID: 2211700
[TBL] [Abstract][Full Text] [Related]
13. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
Blinder MA; Tollefsen DM
J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
[TBL] [Abstract][Full Text] [Related]
14. Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulphate.
Mascellani G; Liverani L; Bianchini P; Parma B; Torri G; Bisio A; Guerrini M; Casu B
Biochem J; 1993 Dec; 296 ( Pt 3)(Pt 3):639-48. PubMed ID: 8280062
[TBL] [Abstract][Full Text] [Related]
15. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
[TBL] [Abstract][Full Text] [Related]
16. Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex.
Maekawa H; Sato H; Tollefsen DM
Thromb Res; 2000 Dec; 100(5):443-51. PubMed ID: 11150588
[TBL] [Abstract][Full Text] [Related]
17. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III.
Koyama T; Parkinson JF; Sié P; Bang NU; Müller-Berghaus G; Preissner KT
Eur J Biochem; 1991 Jun; 198(3):563-70. PubMed ID: 1646716
[TBL] [Abstract][Full Text] [Related]
18. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
Sheehan JP; Tollefsen DM; Sadler JE
J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
[TBL] [Abstract][Full Text] [Related]
19. Structure and anticoagulant properties of sulfated glycosaminoglycans from primitive Chordates.
Pavão MS
An Acad Bras Cienc; 2002 Mar; 74(1):105-12. PubMed ID: 11960179
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
Buchanan MR; Brister SJ
Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
